Yourway
6681 Snowdrift Road
Allentown, PA 18106
United States
Toll Free:
Fax:
Email:
What should you expect when signing up for a COVID-19 clinical trial? Vaccine developers are looking for high-risk candidates, and those likely to be exposed to the disease – though 50% will receive a placebo. While protocols differ slightly, participants can expect mild side effects such as fatigue, ache at the injection site, and chills. “Despite the urgent demand for COVID vaccines that work, trial volunteers shouldn’t worry that corners are being cut on safety,” said Dr. William Schaffner, professor of infectious diseases at Vanderbilt University. Yourway’s direct-to-patient service offering is a proven effective approach to personalized. DTP increases patient satisfaction and improves recruitment and retention rates, leading to cost savings, shorter development timelines, and improved health outcomes.
Human trials of a potential coronavirus vaccine will begin in Indonesia – this initiative is part of a collaboration between Indonesian pharmaceutical company Bio Farma and China’s Sinovac Biotech Ltd. The phase III clinical trial is set to begin on Aug. 11 and will involve 1,620 volunteers between the ages of 18 and 59. As of now, the trial is halfway recruited. In addition to premium shipping and direct-to-patient services, Yourway also offers clinical packaging to ensure all clinical materials are safely contained and can reach their destination on spec.
Revive Therapeutics Ltd., a life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is proceeding with a phase III clinical trial of Bucillamine in patients with mild-moderate COVID-19 following FDA approval. Revive expects trials to take place in up to 10 clinical trial sites across the U.S.; patient screening will begin in Q3. Yourway is headquartered Allentown, Pennsylvania – with a reliable transportation network, we are able to make deliveries across the country (and around the world) within hours, not days.
After showing promise in a phase I study, India-based pharma company Zydus Cadila has launched Phase II clinical trials of its COVID-19 vaccine candidate, called ZyCoV-D. Zydus Cadila chairman Pankaj Patel commented, “All the subjects in Phase I clinical trial were closely monitored in a clinical pharmacological unit for 24 hours post-dosing for safety, and for seven days thereafter, and the vaccine was found to be very safe.” Phase II trials will enroll 1,000 volunteers. With over 20 global depots located around the world including Mumbai, India, Yourway is the logistics partner of choice to advance clinical trials successfully.